Epithelial Cytokines and Chronic Airway Diseases by Integritas Communications

FACULTY

Kathleen M. Buchheit, MD

Assistant Professor of Medicine, HMS Associate Director, Fellowship Training Program Division of Allergy & Clinical Immunology Brigham & Women’s Hospital

Boston, Massachusetts

Dr. Katie Buchheit completed her medical degree at the Albert Einstein College of Medicine in Bronx, New York, her residency in internal medicine at Beth Israel Deaconess Medical Center in Boston, Massachusetts, and her Allergy/Immunology fellowship at the Brigham and Women’s Hospital (BWH) in Boston, Massachusetts. During fellowship, she performed her research training in the laboratory of Drs. Tanya Laidlaw and Joshua Boyce, where she focused on the pathogenesis of nasal polyposis and aspirin-exacerbated respiratory disease (AERD). She is now the Assistant Director of the AERD Center at BWH. Her research continues to be focused on understanding AERD and nasal polyposis, and she is dedicated to investigating the causative mechanisms and exploring new treatments for these diseases. She has been the principal investigator of a National Institutes of Health (NIH)-funded studies investigating the role of B cells and plasma cells in the pathogenesis of AERD and nasal polyps, and mechanistic factors associated with nasal polyp recurrence. Clinically, she focuses her practice primarily on the treatment of patients with chronic rhinosinusitis and AERD.

Joseph K. Han, MD, FARS, FAAAAI, FAAOA

Professor of Otolaryngology

Vice Chair of Clinical Affairs and Administration

Chief, Division of Rhinology and Endoscopic Sinus and Skull Base Surgery

Chief, Division of Allergy

Eastern Virginia Medical School

Norfolk, Virginia

Dr. Joseph Han is Chief of the Division of Rhinology and Endoscopic Sinus and Skull Base Surgery, as well as Chief of the Division of Allergy. Dr. Han holds a Bachelor of Science degree from the University of Washington, earned his MD from the Medical College of Pennsylvania, and completed an otolaryngology-head and neck surgery residency at the Medical College of Wisconsin and a fellowship in rhinology at Oregon Health Sciences University.

Dr. Han has received numerous awards, including Best Doctors of America and Top Doctors by US News & Report. He is a national and international leader in rhinology, allergy, and endoscopic skull base surgery. He was president of the American Rhinologic Society (ARS), Virginia Society of Otolaryngology, Tidewater Otolaryngology & Ophthalmology Society, and Korean American Otolaryngology Society and chair of the Rhinology and Paranasal Sinus Committee of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS). He is Chair of the Rhinitis, Rhinosinusitis, and Ocular Allergy Committee for the American Academy of Allergy, Asthma & Immunology.

Dr. Han was an associate editor for 2 scientific journals and is currently on the editorial board of the International Forum of Allergy & Rhinology. He is a guest examiner for the American Board of Otolaryngology – Head and Neck Surgery. Dr. Han is Editor of Practical Medical and Surgical Management of Chronic Rhinosinusitis and a Section Editor of Ballenger’s Otolaryngology: Head and Neck Surgery. He was involved in the AAO-HNS Guidelines Task Force. He has more than 100 scientific publications, 175 national and international scientific presentations, and 150 guest lectureships.

Dr. Han is very active in both basic science research and clinical research studies. His thesis was on subclassification of chronic rhinosinusitis (CRS), endotyping and phenotyping CRS. He has been awarded National Institutes of Health (NIH) funding for the study of chronic sinusitis and has been lead investigator for several multinational, multi-institutional, prospective clinical trials on chronic sinusitis and nasal polyposis, including the use of biologics for nasal polyps. His clinical interests include allergies, nasal obstruction, sinusitis, cerebrospinal fluid leakage, and nasal/skull base tumors. He is one of the pioneers of endoscopic skull base surgery.

Flavia Hoyte, MD

Professor of Medicine

Division of Allergy and Immunology

Director, Allergy and Clinical Immunology Fellowship Program

National Jewish Health/University of Colorado Denver, Colorado

Dr. Flavia Hoyte is a Professor of Medicine in the Division of Allergy and Immunology at National Jewish Health, with a joint appointment at the University of Colorado. She specializes in adult allergic and immunologic conditions, asthma, and pulmonary conditions. Dr. Hoyte graduated from Princeton University with a degree in molecular biology and received her medical degree from New York University School of Medicine. She subsequently completed a combined residency in internal medicine and pediatrics at the University of Chicago Hospitals and a fellowship in allergy and immunology at National Jewish Health and the University of Colorado. Following graduation, she remained on faculty and currently serves as clinician, educator of residents and fellows, and clinical researcher in several investigator-initiated studies and companysponsored trials. Her research interests include novel diagnostic and therapeutic interventions for chronic sinusitis and asthma. She has served as program director for the National Jewish/University of Colorado Adult Allergy and Immunology Fellowship Training Program since 2015. Dr. Hoyte is a member of the Colorado Allergy and Asthma Society (CAAS), the Western Society of Allergy, Asthma and Immunology (WSAAI), and the American Academy of Allergy, Asthma, and Immunology (AAAAI) and is a fellow of the American College of Allergy, Asthma, and Immunology (ACAAI).

TARGET AUDIENCE

The educational design of this activity addresses the needs of clinical immunologist/allergist and ear, nose, and throat (ENT) specialists, as well as pulmonologists, who manage patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able to:

• Describe the contributions of epithelial cytokine signaling to the pathogenesis of CRSwNP

• Evaluate patients with CRSwNP for symptom burden, disease phenotype, and effects on health-related quality of life

• Discuss the clinical profiles of current and emerging biologic therapies, including anti–thymic stromal lymphopoietin agents, for patients with CRSwNP

• Tailor CRSwNP treatment regimens based on patient symptoms, endotype, treatment goals, and comorbidities

PROGRAM OVERVIEW

Chronic inflammatory diseases of the upper and lower airways, especially CRSwNP, have been tied to significant risks and burdens for affected patients. Although biologic therapies that target overactive cytokine signaling are available, newer therapies are emerging, with targets upstream in the pathogenic cascade to improve efficacy across both type 2 (T2)-high and T2-low profiles. Join us for this engaging Expert Roundtable where faculty will present a 3D animation of pathophysiologic processes in the upper airway epithelium and you can gain multidisciplinary insights on burdens and management challenges associated with CSRwNP and learn about current and emerging treatment options.

PROGRAM AGENDA

6:30 pm Registration/Dinner

7:00 pm Preactivity Questionnaire and Faculty Introductions

7:10 pm Epithelial Pathophysiology in Upper Airways

7:45 pm Consequences and Burdens of CRSwNP

7:55 pm Addressing Challenges in the Biologic-Based Management of Crown

8:15 pm Postactivity Questionnaire and Q&A Session

DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Kathleen M. Buchheit, MD: Consulting Fees: AstraZeneca plc, Eli Lilly and Company, GSK plc, Regeneron Pharmaceuticals, Inc., Sanofi; Contracted Research: Regeneron Pharmaceuticals, Inc.

Joseph K. Han, MD: Consulting Fees: AstraZeneca plc, GSK plc, Regeneron Pharmaceuticals, Inc., Sanofi

Flavia Hoyte, MD: Consulting Fees: AstraZeneca plc, Genentech, GSK plc, Sanofi, Teva Pharmaceutical Industries Ltd.; Fees for Non-CE Services

Received Directly From an Ineligible Entity or Their Agents: AstraZeneca plc; Stock Shareholder: Amgen

The planners and managers have no relevant financial relationships with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION & REFUND/ CANCELLATION POLICY

There is no fee for this activity.

AMERICANS WITH DISABILITIES

Any activity registrant who feels s/he may need accommodation based on the impact of a disability should contact Integritas Communications at info@exchangecme.com to discuss their specific needs.

CONTACT INFORMATION

For information about this program, please contact us at info@ exchangecme.com.

CLINICAL PRACTICE GUIDELINES

» Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma, 2023.

https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023WMS.pdf

» European Position Paper on Rhinosinusitis and Nasal Polyps 2020.

Fokkens W.J., et al. Rhinology. 2020;58(suppl S29):1-464. https://www.rhinologyjournal.com/Documents/Supplements/supplement_29.pdf

» Patient-Reported Outcomes Measure (PROM)

Sinonasal Outcome Test-22 (SNOT-22)

https://www.researchgate.net/figure/SNOT-22-Questionnaire_fig1_246548471

PATIENT ADVOCACY ORGANIZATIONS AND RESOURCES

» Asthma and Allergy Foundation of America (AAFA)

AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases through education, advocacy, and research. http://www.aafa.org/page/asthma.aspx

» American Academy of Allergy, Asthma, and Immunology (AAAAI)

The AAAAI is the leading membership organization of more than 7,100 allergists/immunologists and patients’ trusted resource for allergies, asthma and immune deficiency disorders. https://www.aaaai.org/

» American College of Allergy, Asthma & Immunology (ACAAI)

The ACAAI fosters a culture of collaboration and congeniality in which members work toward the common goals of patient care, education, advocacy, and research. https://acaai.org/asthma

» American Lung Association

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research. http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/asthma/

» American Thoracic Society (ATS)

The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders. https://www.thoracic.org/patients/patient-resources/

» Chest Foundation

The CHEST Foundation creates trusted patient education resources and disease awareness campaigns that empower patients to engage in better managing their health. foundation.chestnet.org/patient-education-resources/asthma/